share_log

和鉑醫藥-B：授出購股權及授出股份獎勵

HBM HOLDINGS-B: GRANT OF SHARE OPTIONS AND GRANT OF SHARE AWARDS

香港交易所 ·  Jan 12 04:52
Summary by Moomoo AI
和鉑醫藥-B於2024年1月12日宣布，根據股東於2020年11月23日通過的購股權計劃及股份獎勵計劃，向2名非關連僱員授出共1,297,000份購股權及501,000份股份獎勵。購股權的行權價格為每股1.73港元，行使期為10年，而股份獎勵的購買價為零。購股權及股份獎勵的歸屬期分別從2025年至2028年不等，並無附帶績效目標。該授出旨在鼓勵員工提升公司及其股份的價值，並與集團利益保持一致。該授出不會使得12個月內授予的購股權及獎勵超過已發行股份的1%。和鉑醫藥-B表示，此舉符合上市規則新訂第17章的過渡安排。
和鉑醫藥-B於2024年1月12日宣布，根據股東於2020年11月23日通過的購股權計劃及股份獎勵計劃，向2名非關連僱員授出共1,297,000份購股權及501,000份股份獎勵。購股權的行權價格為每股1.73港元，行使期為10年，而股份獎勵的購買價為零。購股權及股份獎勵的歸屬期分別從2025年至2028年不等，並無附帶績效目標。該授出旨在鼓勵員工提升公司及其股份的價值，並與集團利益保持一致。該授出不會使得12個月內授予的購股權及獎勵超過已發行股份的1%。和鉑醫藥-B表示，此舉符合上市規則新訂第17章的過渡安排。
AND PLATINUM PHARMACEUTICAL-B ANNOUNCED ON 12 JANUARY 2024 THAT IT HAS GRANTED A TOTAL OF 1,297,000 SHARE OPTIONS AND 501,000 SHARE AWARDS TO 2 UNRELATED EMPLOYEES PURSUANT TO THE SHARE OPTION PLAN AND SHARE AWARD SCHEME APPROVED BY SHAREHOLDERS ON 23 NOVEMBER 2020. The share option has an exercise price of HK$1.73 per share for a period of 10 years and the purchase price of the share bonus is zero. The vesting periods for share rights and share awards vary from 2025 to 2028, respectively, and are not accompanied by performance targets. The award is intended to encourage employees to enhance the value of the company and its shares and to align with the interests of the Group. The grant will not make the warrants and rewards granted within 12 months exceed 1% of the issued shares. AND PLATINUM PHARMACEUTICAL-B STATED THAT THIS MOVE COMPLIES WITH THE TRANSITIONAL ARRANGEMENT OF THE RENEWED CHAPTER 17 OF THE LISTING RULES.
AND PLATINUM PHARMACEUTICAL-B ANNOUNCED ON 12 JANUARY 2024 THAT IT HAS GRANTED A TOTAL OF 1,297,000 SHARE OPTIONS AND 501,000 SHARE AWARDS TO 2 UNRELATED EMPLOYEES PURSUANT TO THE SHARE OPTION PLAN AND SHARE AWARD SCHEME APPROVED BY SHAREHOLDERS ON 23 NOVEMBER 2020. The share option has an exercise price of HK$1.73 per share for a period of 10 years and the purchase price of the share bonus is zero. The vesting periods for share rights and share awards vary from 2025 to 2028, respectively, and are not accompanied by performance targets. The award is intended to encourage employees to enhance the value of the company and its shares and to align with the interests of the Group. The grant will not make the warrants and rewards granted within 12 months exceed 1% of the issued shares. AND PLATINUM PHARMACEUTICAL-B STATED THAT THIS MOVE COMPLIES WITH THE TRANSITIONAL ARRANGEMENT OF THE RENEWED CHAPTER 17 OF THE LISTING RULES.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more